<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) is under investigation for the treatment of a wide range of <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">haematological disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>At commonly used doses of &gt; 120 micrograms/m2/d, extramedullary toxicity is common </plain></SENT>
<SENT sid="2" pm="."><plain>We report the effects of low-dose (LD) rhGM-CSF in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> related to <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and idiopathic <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Nine patients with a mean pre-treatment neutrophil count of 0.6 x 10(9)/l (range 0.2-1.4 x 10(9)/l) received daily rhGM-CSF at doses of between 5 and 15 micrograms/m2 </plain></SENT>
<SENT sid="4" pm="."><plain>Eight patients responded with a mean post-treatment ANC of 3.2 x 10(9)/l (range 1.9-4.6 x 10(9)/l) </plain></SENT>
<SENT sid="5" pm="."><plain>There was no significant therapy-related morbidity </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that in <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, LD rhGM-CSF is an acceptable treatment which has important cost/benefit implications </plain></SENT>
</text></document>